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Abstract
This study was conducted to determine the prevalence of respiratory viral infections 
(RVI) in persons living with HIV (PLH) admitted with a respiratory complaint using 
real-time reverse transcription polymerase chain reaction and primer-independent 
next-generation sequencing (NGS). Of 82 subjects, respiratory viruses were the most 
common pathogen identified in 27 (33%), followed by fungus and bacteria in 8 (10%) 
and 4 (5%) subjects, respectively. Among subjects with RVI, 11 (41%) required ICU 
admission and 16 (59%) required mechanical ventilation. The proportion of respira-
tory viruses identified, and the associated complicated hospital course highlights the 
significant role that RVIs play in the lung health of PLH.
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1  | INTRODUC TION
Pulmonary complications, including respiratory tract infections, 
are a major cause of morbidity and mortality among people living 
with HIV (PLH).1,2 While bacterial and fungal pathogens have been 
well -described as important etiologies of opportunistic lung dis-
ease, less is known about respiratory viruses in PLH.3 Studies from 
antiretroviral therapy (ART)-limited regions revealed a 20-fold 
higher risk of respiratory viral infections among pediatric and adult 
PLH compared with HIV-uninfected subjects.4,5 In these settings, 
HIV infection was also a risk factor for higher rates of hospitaliza-
tion, pneumococcal coinfection, and the need for supplemental ox-
ygen in lower respiratory tract influenza infection.5-7 The aim of our 
study was to determine the prevalence of respiratory viruses in a 
cohort of PLH hospitalized with a respiratory complaint at a tertiary 
care center. Secondarily, commercial real-time reverse transcription 
polymerase chain reaction (rRT-PCR) was compared to pathogen-ag-
nostic next-generation sequencing (NGS) for the detection of viral 
pathogens in respiratory specimens.
2  | MATERIAL S AND METHODS
This prospective, observational study was conducted at a ter-
tiary care center where over 1800 PLH receive care. The popula-
tion is 70% male and 60% black, which is reflective of PLH in the 
United States. PLH ≥ 18 years of age requiring admission between 
08/2015 and 08/2018 were approached for enrollment sequen-
tially on weekdays if they had a respiratory symptom (predefined 
as cough, shortness of breath, sore throat, rhinorrhea, wheezing, 
or stridor) documented as new and present on admission. Informed 
consent was obtained from all subjects. This study was approved by 
the institutional review board at the University of North Carolina.
Clinical information including demographics, presenting symp-
toms, laboratory chemistries and hematology, medical history, 
medications, CD4 cell count and HIV plasma viral load, utilization 
of supplemental oxygen and critical care resources, microbiologic 
results, radiographic evaluation, and clinical outcomes of hospital 
course were collected by chart review.
Nasopharyngeal (NP) swabs for each patient were collected 
in viral transport media and stored at −80°C within 24 hours of 
enrollment. Excess sample from bronchoalveolar lavage was col-
lected and stored at −80°C if a clinically indicated bronchoscopy 
was performed. The eSensor RVP (GenMark) rRT-PCR platform 
was used to detect influenza A, influenza A H1, influenza A H3, 
influenza A 2009 H1N1, influenza B, respiratory syncytial virus A, 
respiratory syncytial virus B, parainfluenza virus 1, parainfluenza 
virus 2, parainfluenza virus 3, parainfluenza virus 4, human metap-
neumovirus, human rhinovirus, and coronavirus (229E, HKU1, 
NL63, OC43). Non-viral microbiologic diagnoses were based on 
testing ordered by the healthcare provider and included bacte-
rial, fungal, and AFB cultures, and direct fluorescence antibody 
(DFA) for Pneumocystis jirovecii pneumonia (PJP) from respiratory 
samples.
Samples collected from individuals enrolled between August 
2015 and August 2016 were also tested for RNA respiratory viruses 
using primer-agnostic next-generation deep genome sequencing 
(Supplemental Methods).
3  | RESULTS
3.1 | Screening/enrollment
Of 101 subjects that met criteria for enrollment, 12 refused par-
ticipation, four were discharged prior to recruitment, two were 
Spanish-speaking only, and one was decisionally impaired with no 
available legally authorized representative.
Eighty-two subjects including 49 (60%) men with a mean age of 
50 were included in the final analysis (Table 1). Demographic, clini-
cal characteristics, and outcomes were similar between those with 
and without a respiratory virus with the exception of a significantly 
higher BMI in the group with a virus. Approximately 1/3 each were 
current or former smokers, and less than half received an influenza 
vaccine in the prior season. While more than 70% were prescribed 
antiretroviral therapy, 39% had plasma HIV RNA levels that were 
above the limits of detection. More than half of the participants had 
CD4 cell counts below 200/mm3.
3.2 | Respiratory virus detection
Thirty-four subjects (41%) were diagnosed with a respiratory infec-
tion including 27 (33%) with a respiratory virus detected alone or 
in combination with other pathogens—including one subject with 
two viruses detected simultaneously, three with both Pneumocystis 
jirovecii pneumonia (PJP) and viral coinfection, and 2 (2%) with bac-
terial/viral coinfection (Figure S1). Of the seven remaining subjects, 
PJP was detected in 5 and bacterial pneumonia in 2. Rhinovirus was 
the most common respiratory viral pathogen detected in 14 subjects 
(52%), followed by influenza (19%), parainfluenza (11%), coronavi-
rus (7%), and adenovirus (7%). Five respiratory viral infections were 
identified retrospectively through rRT-PCR testing conducted as 
part of this study (Figure S1).
For 29 participants, 39 respiratory samples (29 NP and 10 BAL) 
were also tested for RNA viruses using NGS (Figure S2). Three par-
ticipants had discordant results compared with rRT-PCR testing: 
One had adenovirus detected by rRT-PCR but not by RNA-based 
NGS, and two subjects had coronavirus and parainfluenza 4 de-
tected by rRT-PCR but no virus was identified by NGS. NGS did 
not detect any additional viruses compared to rRT-PCR; however, 
complete genome sequences were obtained for rhinovirus in three 
subjects that were genetically distinct from all known rhinoviruses 
(Figure S3).
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TA B L E  1   Demographics, clinical characteristics, and outcomes of PLH admitted To a US tertiary care center with a respiratory complaint 
over 3 y, n = 82
Variables
Total subjects 
(n = 82)
Subjects positive for 
respiratory virus (n = 27)
Subjects negative for 
respiratory virus (n = 55) P-value
Male gender 49 (60%) 14 (52%) 35 (64%) 0.31
Age, mean (SD) 50 (3.41) 51 (2.84) 49.1 (1.94) 0.51
Race    0.38
Caucasian 24 (30%) 6 (23%) 18 (33%)  
African American 55 (68%) 20 (77%) 35 (64%)  
Other 2 (2%) 0 2 (4%)  
Missing 1 (1%) 1 (6%) 0  
BMI, mean (SD) 26 (0.84) 29 (1.82) 24 (0.85) 0.04*
Received influenza vaccine during previous season 38 (46%) 14 (52%) 24 (44%) 0.73
Comorbidities present
Chronic pulmonary disease 33 (40%) 15 (56%) 18 (33%) 0.05
Cardiac disease 18 (22%) 3 (11%) 15 (28%) 0.09
Liver disease 15 (18%) 6 (22%) 9 (16%) 0.52
Renal disease 29 (36%) 8 (30%) 21 (39%) 0.41
Malignancy 20 (25%) 3 (12%) 17 (31%) 0.06
Rheumatologic disease 6 (7%) 2 (7%) 4 (7%) 0.98
Currently smoking 31 (38%) 17 (63%) 14 (25%) 0.001*
Prior or current intravenous drug use 6 (7%) 4 (15%) 2 (4%) 0.19
On ART 60 (73%) 19 (70%) 41 (75%) 0.69
CD4 + T-cell counta     0.25
<50 cells/µL 24 (30%) 7 (26%) 17 (31%)  
51-200 cells/µL 19 (23%) 4 (15%) 15 (28%)  
>200 cells/µL 38 (47%) 16 (59%) 22 (41%)  
Missing 1 (2%) 0 1 (3%)  
HIV RNA
Not detected 49 (60%) 17 (63%) 32 (59%) 0.75
Detectable (VL range) 32 (39%) 
(42-933,923)
10 (37%) (49-933,923) 22 (40%) (42-656,766)  
Missing 1 (2%) 0 1 (3%)  
Lower respiratory tract findings on chest imagingb  62/75 (83%) 19/26 (70%) 43/49 (88%) 0.06
Duration of hospital stay, mean days (SD) 11.2 (1.24) 13.0 (3.13) 10.4 (1.05) 0.33
Intensive care unit required 32 (39%) 11 (41%) 21 (38%) 0.82
Discharged to a higher level of care 18 (22%) 7 (26%) 11 (20%) 0.37
Death 8 (10%) 3 (11%) 5 (9%) 0.77
ARDS 9 (11%) 4 (15%) 5 (9%) 0.44
Acute renal failure 15 (18%) 2 (7%) 13 (24%) 0.07
Myocarditis 2 (2%) 1 (4%) 1 (2%) 0.60
Mechanical ventilation 16 (20%) 5 (19%) 11 (20%) 0.87
Number of days, mean (SD) 7.8 (1.51) 10.4 (1.96) 6.7 (1.97) 0.28
Non-invasive positive pressure ventilation 13 (16%) 6 (23%) 7 (13%) 0.24
Number of days, mean (SD) 1.38 (0.38) 1.83 (0.83) 1 (0) 0.30
Vasopressors 10 (12%) 3 (11%) 7 (13%) 0.83
Number of days, mean (SD) 8.7 (3.1) 15.3 (9.35) 5.9 (1.98) 0.18
Note: Shown are the demographics for the study cohort overall and grouped by those that tested positive for a respiratory virus and those that tested 
negative for a respiratory virus. P-values were calculated using Student's t test for continuous variables and chi-squared test for categorical variables.
Abbreviations: BMI, body mass index; ART, antiretroviral therapy; ARDS, acute respiratory distress syndrome.
aCD4 counts <10 were considered equal to 10 for analysis. 
bOf those who had chest imaging during admission. 
*Indicates a P-value < 0.05. 
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3.3 | Clinical outcomes
PLH admitted with a respiratory virus required a high level of care 
with 41% admitted to the intensive care (ICU) unit and 59% requir-
ing mechanical ventilation. Four subjects with a respiratory virus 
(15%) were discharged to a higher level of care than on admission, 
and 3 (11%) died (Table 1). Subjects who died during hospital admis-
sion had a lower mean CD4 (43 cells/µL) and higher HIV viral load 
(165 962 copies/mL) compared to those who were discharged home 
or to a rehabilitation facility, but pairwise comparisons were not sta-
tistically significant (Table S1).
4  | DISCUSSION
In this cohort of 82 PLH admitted with a respiratory complaint, 
respiratory viruses were the most commonly identified respiratory 
pathogens, more than bacterial and fungal pathogens combined.
Among PLH enrolled in this study, those diagnosed with a respi-
ratory virus were found to have increased BMI (29 vs 24, P = .04) 
compared with those without a respiratory virus. In addition to the 
fact that increased BMI is a known risk factors for complicated 
influenza infection in the general population, this suggests that in-
terventions targeting weight loss could reduce risk among PLH.8 
Similarly, current smoking was significantly more prevalent in 
those diagnosed with a respiratory virus compared to those with-
out (63% vs 25%, P = .001). This mirrors the association between 
smoking and influenza infection seen in the general population and 
further supports recommendations for tobacco cessation in this 
population.9 Since HIV-uninfected individuals were not simultane-
ously enrolled, it is not possible to determine whether HIV itself is 
a risk factor for severe disease; however, the high rates of subjects 
requiring ICU admission (41%), mechanical ventilation (59%), and 
discharge to a higher level of care than on admission (15%) highlight 
the severity of illness associated with respiratory viral infections in 
PLH. These findings support prior studies in resource-limited set-
tings or that included subjects with poor HIV control found higher 
rates of hospitalization, longer lengths of stay, and increased need 
for supplemental oxygen in PLH compared to HIV-uninfected sub-
jects with viral infection.5-7 These findings combined with the low 
rates of influenza vaccination—only 25% of subjects’ influenza 
were vaccinated, and overall cohort had a 46% vaccination rate—
indicate a missed opportunity to reduce morbidity and mortality 
among PLH.
A substantial proportion of those admitted with a respiratory 
infection had suboptimally controlled HIV infection, and we are 
unable to determine whether this was due to recent HIV diagno-
sis, non-adherence, or another cause. However, the high burden of 
respiratory viral infections and marked severity of illness occurred 
across a wide range of HIV control, including 17 (63%) subjects 
with undetectable HIV viral loads. While the most severe disease 
was more common in subjects with lower CD4 counts and higher 
viral loads, 6/11 (55%) of subjects requiring ICU level care had an 
undetectable HIV viral load. Understanding the mechanisms that 
drive the severity of illness associated with respiratory viral infec-
tions in people living with HIV will be important to develop more 
effective therapeutic strategies.
The rate of respiratory viral infections among PLH found in 
this study also argues for routine respiratory viral diagnostics in 
the care of PLH with respiratory complaints. Of the 27 subjects 
diagnosed with a respiratory viral infection, four were identi-
fied retrospectively during research testing as part of this study. 
An undiagnosed viral infection can have significant clinical im-
plications, including unnecessary antibiotic administration and/
or the use of therapies that could be harmful in the setting of 
viral infection such as corticosteroids,10,11 in addition to potential 
nosocomial spread. NGS represents an expansion of diagnostic 
capacity with the potential to identify viruses not included in the 
primer-dependent panel including new or re-emerging viruses. 
The ability of NGS to detect genetically distinct rhinoviruses pro-
vides proof of principle regarding the utility of NGS to detect viral 
variants.
Strengths of this study include evaluation of a large cohort of 
PLH with respiratory symptoms to characterize the burden of re-
spiratory viruses in symptomatic PLH. Combination of both tradi-
tional rRT-PCR and NGS diagnostics also represents a novel and 
thorough method of characterization. However, there are import-
ant limitations that should be considered. Foremost, this study was 
conducted in a single academic center and was limited to adults. 
Additionally, our characterization of infectious etiologies was mo-
lecular-based for viruses but relied on less sensitive methods for 
the detection of bacteria and PJP. However, in support of these 
findings, viruses were also the most commonly identified pathogen 
in community-acquired pneumonia in the EPIC study, which used 
rigorous microbiologic testing, suggesting that the prevalence of 
viruses identified in this study is not due to disparate diagnostic 
sensitivity.12 We also cannot exclude that viruses identified could 
represent asymptomatic carriage in the nasopharynx; however, all 
subjects were symptomatic on admission, and with the exception 
of four subjects that had concomitant PCP or bacterial infection, 
no other respiratory pathogens were identified. Lastly, the use 
of NGS in this study was exploratory and limited to a subset of 
participants. The limit of detection by the number of reads being 
sequenced emerged as a constraint of NGS as seen previously.13,14 
Likely for this reason, a coronavirus was identified by RT-PCR, but 
not by NGS. One obvious solution to overcome this limitation is 
to sequence to greater depth. Advances in NGS technology since 
this study make this a cost-neutral improvement. Another option 
is the transition to longer read platforms as longer reads are able 
to detect viruses with less homology to existing genomes, that is, 
novel pathogens. Lastly, one could add a pre-selection/ pre-ampli-
fication step, analogous to current, gene-targeted specialized NGS 
panels for cancer and other disease. Such a strategy would trade 
an increase in sensitivity, for the ability of NGS to detect novel 
respiratory pathogens, that is, genomes that were not included in 
rRT-PCR or NGS-enrichment-PCR panels.
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In conclusion, respiratory viruses were the most common respi-
ratory pathogen identified in admitted PLH. These subjects experi-
enced severe illness as 41% required ICU admission, 59% required 
mechanical ventilation, and 11% died. Respiratory viral infections 
represent an important cause of severe illness in PLH admitted with 
respiratory symptoms. Future research should be directed at under-
standing if PLH are at increased risk of respiratory viral infections 
or increased severity compared with HIV-uninfected individuals in 
the setting of widespread ART availability and in low prevalence HIV 
settings, and if so, potential mechanisms underlying that increased 
risk.
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